| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | -0.18 | 0.0008 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0009 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.17 | 0.001 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.001 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.13 | 0.001 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.002 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.27 | 0.002 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | -0.15 | 0.002 |